RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
National cervical cancer screening campaign under way Today sees the kick-off of the national campaign: Let’s talk about cervical cancer – have you #done the smear test or self-test yet? This marks the first time that RIVM, Bevolkingsonderzoek Nederland and the KWF Dutch Cancer Society are launching a joint campaign to call attention to cervical cancer screening.
Predicting who will experience symptoms after Lyme disease remains challenging Each year, approximately 27,000 people are diagnosed with Lyme disease. For most, the symptoms disappear after treatment with antibiotics. Unfortunately, 25% of those treated have chronic symptoms, such as fatigue, concentration disorders or pain.
New Zoonoses Report out now: avian flu most notable outbreak in 2022 Throughout 2022, the Netherlands faced a persistent avian flu outbreak, affecting 76 poultry farms. The virus also infected numerous wild birds and various wild mammals. These findings are presented in the Zoonoses Report, an annual publication issued jointly by RIVM and the Netherlands Food and Consumer Product Safety Authority (NVWA).
Number of Lyme disease diagnoses remains high In 2021, the number of Lyme disease diagnoses with a red ring or rash– known as an erythema migrans, or EM – remained as high as in the previous survey in 2017. GPs diagnosed 25,600 patients with a red ring or rash caused by the Lyme bacteria.
Self-sampling device to be sent automatically, making it easier to take part in cervical cancer screening From the first week of July, every woman turning 30 will receive a self-sampling device with their invitation for cervical cancer screening. Participants can use this device to collect their own vaginal material.
Spring sunshine forecast: enjoy, but do not get a sunburn According to the Royal Netherlands Meteorological Institute, the sun will be shining frequently the upcoming days. If you are planning to go out and enjoy the sunshine, please do so responsibly.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.